Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ludovic Lacroix

Showing results (171-180 of 180) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 180 results.
Journal of Experimental & Clinical Cancer Research : CR|July 6, 2022
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancersCapucine Baldini, Francois-Xavier Danlos, Andreea Varga, et al.
Nature|September 7, 2022
Genomics to select treatment for patients with metastatic breast cancerFabrice Andre, Thomas Filleron, Maud Kamal, et al.
Ebiomedicine|June 1, 2022
Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patientsNicolas Chapuis, Nusaibah Ibrahimi, Thibaut Belmondo, et al.
Radiology|November 26, 2024
Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with MetastasesLama Dawi, Younes Belkouchi, Littisha Lawrance, et al.
Cancer Discovery|January 20, 2023
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural MesotheliomaFrançois-Xavier Danlos, Matthieu Texier, Bastien Job, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2019
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung CancerGonzalo Recondo, Laura Mezquita, Francesco Facchinetti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2026
Phase I/II study of the PARP inhibitor olaparib and irinotecan in children and young adults with recurrent/refractory malignancies: Arm D of the AcSé-ESMART trialSusanne A Gatz, Pablo Berlanga, Gwénaël Le Teuff, et al.
Thyroid : Official Journal of the American Thyroid Association|October 16, 2023
Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter StudyBin Xu, Kartik Viswanathan, Mahsa S Ahadi, et al.
Oncotarget|May 7, 2015
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancerVladimir Lazar, Eitan Rubin, Stephane Depil, et al.
Nature|October 9, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Pageof 18

Showing results (171-180 of 180) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 180 results.
Journal of Experimental & Clinical Cancer Research : CR|July 6, 2022
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancersCapucine Baldini, Francois-Xavier Danlos, Andreea Varga, et al.
Nature|September 7, 2022
Genomics to select treatment for patients with metastatic breast cancerFabrice Andre, Thomas Filleron, Maud Kamal, et al.
Ebiomedicine|June 1, 2022
Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patientsNicolas Chapuis, Nusaibah Ibrahimi, Thibaut Belmondo, et al.
Radiology|November 26, 2024
Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with MetastasesLama Dawi, Younes Belkouchi, Littisha Lawrance, et al.
Cancer Discovery|January 20, 2023
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural MesotheliomaFrançois-Xavier Danlos, Matthieu Texier, Bastien Job, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2019
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung CancerGonzalo Recondo, Laura Mezquita, Francesco Facchinetti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2026
Phase I/II study of the PARP inhibitor olaparib and irinotecan in children and young adults with recurrent/refractory malignancies: Arm D of the AcSé-ESMART trialSusanne A Gatz, Pablo Berlanga, Gwénaël Le Teuff, et al.
Thyroid : Official Journal of the American Thyroid Association|October 16, 2023
Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter StudyBin Xu, Kartik Viswanathan, Mahsa S Ahadi, et al.
Oncotarget|May 7, 2015
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancerVladimir Lazar, Eitan Rubin, Stephane Depil, et al.
Nature|October 9, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Pageof 18